This section of the website is for patients who have been prescribed IQIRVO®▼ (elafibranor) in the UK. Information for members of the general public can be found here.
This medicinal product has a conditional marketing authorisation.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.

All materials

PBC & Me: What is IQIRVO (elafibranor)

Primary Biliary Cholangitis (PBC) Video
07:28

This video gives you a clear overview of how your treatment works and what to expect as you start or continue elafibranor.

You’ll find out:
• How elafibranor targets key processes in the liver
• What benefits have been seen in clinical studies
• Why regular check-ups and blood tests are important

It also encourages you to take an active role in your care and make the most of the support available to you.

ELA-UK-000417 | July 2026

Explore more Primary Biliary Cholangitis (PBC) Patient Support

Explore more Primary Biliary Cholangitis (PBC) Patient Support

Browse

To access relevant information about Primary Biliary Cholangitis, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

I am a patient

This section provides information to support patients that have been prescribed IQIRVO®▼ (elafibranor).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.